EDX Medical Group Plc Director Dealing
March 13 2023 - 3:00AM
UK Regulatory
TIDMEDX
This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation No 596/2014 which is part of English law
by virtue of the European (Withdrawal) Act 2018, as amended. On publication of
this announcement via a regulatory information service, this information is
considered to be in the public domain and such persons shall therefore cease to
be in possession of inside information.
LONDON: March 13 March, 2023
EDX Medical Group Plc
Director Dealing
EDX Medical Group plc ("EDX Medical" or the "Company"), which develops
innovative digital diagnostic products and services for cancer, heart disease,
neurology and infectious disease testing, today announces that Jason Holt,
Non-executive Chairman of the Company, purchased 400,000 ordinary shares in the
Company at an aggregate price of 3.025 pence per ordinary share on 10 March
2023. Following this purchase, Jason Holt owns 4,400,000 ordinary shares,
representing 1.74% of the issued share capital.
The directors of the Company accept responsibility for the contents of this
announcement.
For more information, please contact:
EDX Medical PLC
Mike Hudson
Tel: 07812345301
Peterhouse:
Guy Miller
Tel: 020 7220 9795
Media House International,
Ramsay Smith
Tel: +44 (0) 7788 414856:
email: ramsay@mediahouse.co.uk
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities / person
closely associated
a) Name Jason Holt
2 Reason for the notification
a) Position/status Non-executive Chairman
b) Initial notification / Initial notification
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name EDX Medical Group Plc
b) LEI 213800BZVJZTMCZ6DJ63
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial Ordinary shares of 1 pence each in EDX
instrument, type of Medical Group Plc
instrument
Identification code Identification code (ISIN) for EDX Medical
Group Plc ordinary shares: GB00BNDMJS47
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s) Price(s) Volume(s)
3.025p 400,000 ordinary shares
d) Aggregated information N/A
- Aggregated volume
- Price
e) Date of the transaction 10 March 2023
f) Place of the transaction AQSE Growth Market
Notes for Editors:
About EDX Medical Group
EDX Medical develops and delivers innovative digital diagnostic products and
services for cancer, heart disease, neurology and infectious disease testing,
helping to predict disease risk, inform clinical decision-making and accelerate
the development of new medicines. The company is listed on the Access Segment
of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and
life sciences entrepreneur with more than 30 years of experience in the sector,
specialising in cancer treatments and diagnostics.
By translating clinical insights into pragmatic solutions combining advanced
biological and digital technologies, EDX Medical seeks to cost-effectively
improve the detection of disease risk and personalise disease management in a
timely fashion. Early disease detection and risk prediction is the most
impactful way of reducing deaths and lowering the future costs of healthcare
provision globally.
EDX Medical operates a molecular biology and diagnostics laboratory in
Cambridge, UK, from which it performs research & development (R&D), provides
testing and genomic sequencing services, undertakes quality assurance and has
established expertise in the design, development, validation and sourcing of
diagnostic testing solutions. Key tests performed in this laboratory have been
audited by the United Kingdom Accreditation Service (UKAS) and accredited to
ISO 15189.
www.edxmedical.co.uk
https://www.toraxbiosciences.co.uk/
END
(END) Dow Jones Newswires
March 13, 2023 03:00 ET (07:00 GMT)
EDX Medical (AQSE:EDX)
Historical Stock Chart
From Apr 2024 to May 2024
EDX Medical (AQSE:EDX)
Historical Stock Chart
From May 2023 to May 2024